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Recent systematic reviews1-3 and the results from our previous work from the MERIDIAN 2 
study4 have shown that in utero Magnetic Resonance (iuMR) imaging significantly improves 3 
the detection of fetal brain abnormalities when compared with antenatal ultrasonography 4 
(USS). Specifically, iuMR improves diagnostic accuracy4 and diagnostic certainty5 when a 5 
brain abnormality is shown or suspected on USS and those findings are likely to have 6 
substantial implications for clinical practice.4 An important limitation of those studies is they 7 
have not evaluated the impact of iuMR imaging in cases in which no brain abnormality was 8 
detected or suspected on USS. The intrinsic value of a diagnostic test relies not only its 9 
ability to identify an abnormality correctly when one is present but also to exclude 10 
abnormalities correctly when they are not present. To date, studies of iuMR for fetal brain 11 
abnormality have been undertaken among fetuses in which a brain abnormality was suspected 12 
(predominantly on the basis of abnormal USS) and, whilst these strongly support the use of 13 
iuMR in such cases, the benefit ± if any ± of iuMR in ostensibly normal pregnancies is 14 
unknown. 15 
 16 
In this study we present the results of an extension to the MERIDIAN study in which women 17 
with low-risk pregnancies and normal fetuses on USS were recruited in order to have iuMR 18 
imaging of the fetal brain (full protocol available at 19 
https://www.sheffield.ac.uk/meridian/studysummary). This enabled the calculation of 20 
negative predictive value (NPV) for both iuMR and USS imaging in order to complement the 21 
positive predictive value (PPV) derived from the main MERIDIAN cohort.  To our 22 
knowledge, no previous study has evaluated the impact of iuMR in this population. We also 23 
discuss the problems of measuring diagnostic performance for iuMR and antenatal USS with 24 
particular reference to the inherent difficulties in estimating sensitivity and specificity. 25 
2 
 
MATERIALS AND METHODS 26 
Participants and Recruitment  27 
This work was funded by the NIHR-HTA by way of an extension to the main MERIDIAN 28 
study (ISRCTN 27626961) and conducted under the same ethics approval.4 We aimed to 29 
recruit approximately 200 women carrying a fetus in whom no brain (or somatic) abnormality 30 
was detected on the 20-week anomaly USS that is routinely offered to women in the UK. 31 
Any subsequent USS examinations (if performed) also had to show normal fetal anatomy. All 32 
of the pregnancies were otherwise considered µORZ-ULVN¶ZLWKQRNQRZQVHURORJLFDORU 33 
chromosomal/genetic concerns.   Potential participants were informed about the study by way 34 
of posters and leaflets in 12 of the original 16 fetal medicine referral centres involved in the 35 
original MERIDIAN and by press coverage in those regions. Interested pregnant women 36 
contacted the central site (Academic Unit of Radiology, University of Sheffield) and were 37 
sent a patient information leaflet by email or post, which gave full details of the study. A 38 
follow-up telephone call enabled queries to be answered, initial screening questions to be 39 
assessed and eligibility for the study confirmed. A copy of the most recent antenatal USS 40 
report was then obtained to confirm the normal development of the pregnancy. Other 41 
inclusion criteria were: the woman was at least 16 years old and the fetus a minimum of 18 42 
gestational weeks (gw) at the time of iuMR imaging was to be performed. Exclusion criteria 43 
were inability to give informed consent, contraindications to MR imaging, or 44 
inability/unwillingness to travel to Sheffield for iuMR imaging. There were no set 45 
requirements for the interval between considered eligible for the study and having the iuMR 46 
scan.  47 
 48 
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Written informed consent was taken on the day of the study after further explanation of the 49 
iuMR procedure, including potential risks and the right to withdraw from the study at any 50 
time. The consent procedure also confirmed willingness of the woman to inform her GP that 51 
she had been involved in the study and to send them a copy of the iuMR report if no 52 
unexpected findings were shown. If a brain abnormality was detected on iuMR imaging the 53 
woman agreed that the findings would be discussed verbally with her obstetrician who would 54 
subsequently receive a full clinical-style report in accordance with the guidance from the 55 
Ethics Committee. Participants were not paid for volunteering for the study but a £10 gift 56 
voucher was given, along with travel expenses, for the participant and an accompanying 57 
person.  58 
Sample size and reference diagnoses 59 
Starting from the assumption that no USS false negatives will be found, the study aimed to 60 
recruit 200 fetuses on the basis of the 3/n rule,6 a large sample approximation of the upper 61 
95% confidence interval for very rare events. This allowed the negative predictive value of 62 
USS to be estimated to an upper confidence limit of 1.5% in the absence of any abnormal 63 
scans, and to within a standard error of <=2% for an incidence of <10%. 64 
The brain of the fetus was assumed to be normal if both USS and iuMR were normal, an 65 
approach supported by the low rate of false positive finding for iuMR in the main MERIDAN 66 
study (1/570 = 0.18%). These became the True Negatives for USS and iuMR used in this 67 
study. Additional tests were undertaken in the event of a brain abnormality reported on iuMR, 68 
and these were intended to be the reference against which USS and iuMR were compared, 69 
although this approach was found to be too simplistic for practical cases as discussed below.  70 
 71 
iuMR scanning procedures and protocols 72 
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All of the iuMR examinations were performed at the Academic Unit of Radiology, University 73 
of Sheffield on either a 1.5T whole body scanner (HDx, GE Healthcare, Milwaukee) or a 3T 74 
whole body scanner (Ingenia, Philips, Netherlands). The 3T scanner was used only when the 75 
1.5T was not available (e.g. breakdowns) and this occurred in two cases only. The iuMR 76 
imaging targeted the fetal brain only and the woman was on the scanner for maximum of 30 77 
minutes. The imaging protocol performed at 1.5T consisted of ultrafast imaging in the three 78 
orthogonal planes (T2 weighted ssFSE and 2D-FIESTA), T1 weighted, FLAIR, Diffusion 79 
weighted in the axial plane and T2-weighted volume acquisitions and MR cine using 3D-80 
FIESTA. After the scan the woman and her companion(s) were shown some of the iuMR 81 
images and given the opportunity to take some images on their phone or camera. The formal 82 
report on the study was issued the following day after review by a paediatric neuroradiologist 83 
with extensive experience of fetal neuroimaging (PDG).  84 
Statistical methods for assessing diagnostic performance  85 
The accuracy of a negative USS was quantified by the NPV, the percentage of fetuses in 86 
whom no abnormality was subsequently detected. For iuMR, NPV agreement was derived 87 
separately for fetuses whose initial USS was normal and abnormal USS (i.e. USS+, iuMR- 88 
and USS-, iuMR-).The PPV of USS and iuMR were derived analogously. PPVs and NPVs 89 
were presented alongside 95% binomial confidence intervals. No attempt was made to 90 
combine the PPV and NPV of iuMR with those from the main MERIDIAN study, or to 91 
estimate the sensitivity and specificity for reasons explained in the discussion.  92 
 93 
 94 
 95 
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RESULTS 96 
Recruitment and scanning took place between November 2013 and May 2017 during which 97 
time 225 pregnant women enquired about the study but three women did not meet the 98 
inclusion criteria because of pregnancy complications. Appointments for iuMR were made 99 
for the other 222 women who did meet the entrance criteria but of those 23 did not attend. 100 
One woman underwent the iuMR study but the procedure was abandoned due to the 101 
participant feeling unwell before any relevant data was obtained and three women withdrew 102 
from the study after iuMR imaging was performed. In total, therefore, 198 participants with 103 
205 fetuses (14 twin pregnancies) were scanned successfully as shown in Figure 1. The 104 
pregnant women recruited were from a wide geographical area, with 68 (34%) participants 105 
living within 18 miles of the Sheffield MR unit and the remaining 137 from further afield 106 
(maximum 189 miles). The age range of the pregnant women was 20 ± 46 years (mean 31.5 107 
years) and the gestational age at the time of iuMR is shown in Figure 2 (26% between 18 and 108 
23 gw, 74% gw). There were no reportable adverse events during the iuMR scanning of 109 
these pregnant women. IuMR studies were reported as normal for 203 cases and brain 110 
abnormalities were reported in two fetuses (from separate pregnancies) as described below. 111 
 112 
Case 1 (Figure 3).  113 
iuMR imaging for this study was performed at 35gw following normal USS examinations in 114 
the second trimester (3a-3c). There was focal abnormal high signal on T2-weighted images  115 
in the right inferior/sub-central gyri with broadening of the gyri. The diagnostic confidence 116 
of abnormality was quoted as 70% (certain) and pathology such as a focal cortical dysplasia 117 
or cortical tuber was suggested, although the possibility of an artefact was considered. Post-118 
natal MR imaging performed at 3 weeks (3d-3f) confirmed the antenatal findings but its 119 
nature remained uncertain. Developmental assessment at 6 months showed plagiocephaly 120 
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and reduced central tone but otherwise a normal repertoire of movements. The Bayley Infant 121 
Neurodevelopmental Screener (a developmental tool across four domains) put the baby in the 122 
µmiddle risk¶ group. Genetic testing for Tuberous Sclerosis Complex was negative. The infant 123 
remains under clinical review and a further MR examination is planned at 3 years.  124 
 125 
Case 2. (figure 4) 126 
Routine anomaly USS was performed at 20gw and showed no abnormalities. iuMR imaging 127 
for this study was undertaken at 26gw and showed mild ventriculomegaly ( trigones 128 
measurements between 10-11mm. The rest of the brain was normal although the fetus had 129 
macrocephaly (bi-parietal diameter >97th centile and occipito-frontal on the 97th centile). 130 
Normal sized ventricles were confirmed on review of the USS performed at 20gw but follow 131 
up USS confirmed non-progressive ventriculomegaly at 30gw. The child was developing 132 
normally in all domains at 14 months. 133 
Analysis 134 
Case 1 is treated as a true brain abnormality, although the nature of the abnormality is still not 135 
known, so is considered to be a False Negative for USS and a True Positive for iuMR. In 136 
contrast, the appearance of VM on iuMR imaging in case 2 after retrospective confirmation 137 
of normality at 20 weeks is interpreted as an evolving feature that could not be recognised at 138 
ZHHNVEHFDXVHLWZDVQ¶WSUHVHQW. However, the confirmation of ventriculomegaly (VM) on 139 
third trimester USS confirm the iuMR finding. This is taken as a True Negative for USS and 140 
a True Positive for iuMR imaging. Table 1 shows the number and characteristics of correct 141 
and incorrect diagnoses made by USS and iuMR using data from both this study and the 142 
MERIDIAN study. Both USS and iuMR have high NPV for the normal risk pregnancies, 143 
being 99.5% (95% CI 97.3 to 100.0%) for USS and 100% (98.2 to 100%).  144 
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In the main MERIDIAN cohort, 388/570 fetuses were correctly diagnosed by USS giving a 145 
PPV of 68.1% (64.1 to 71.9%). Of these, iuMR found abnormalities in 513 fetuses of whom 146 
39 were incorrect diagnoses giving a PPV of 92.4% (90.0 to 94.5%). The remaining 57 were 147 
recorded as normal on iuMR, one of whom was subsequently found to have a brain 148 
abnormality matching the original USS diagnosis, giving an NPV in this population of 98.2% 149 
(90.6%-100.0%).  150 
 151 
. 152 
153 
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DISCUSSION 154 
The MERIDIAN study, along with published systematic reviews, demonstrate a significant 155 
improvement in diagnostic accuracy when iuMR imaging is used in the diagnostic pathway.1-156 
4
 One important implication of this finding is USS might fail to detect some brain 157 
abnormalities during screening. This study shows that does not occur at high frequency and 158 
supports USS being the primary screening method for brain imaging. IuMR should be used as 159 
an adjunct to USS only when brain abnormalities are suspected on USS in low risk 160 
pregnancies. There were two abnormalities noted on iuMR following a normal USS in 205 161 
fetuses, one of which was a case of mild VM that was confidently described as an evolving 162 
pathology and the original USS report was correct at the time of scanning. As such, USS has 163 
a NPV of 99.5% (95% CI 97.3% to 100%), supporting the contention that a normal USS can 164 
safely be assumed to rule out fetal brain abnormality with very high certainty in fetuses with 165 
no other risk factor.  166 
 167 
A review of the literature has not shown any other studies of iuMR imaging in normal 168 
pregnancies as identified by USS, so there are no other comparative estimates of NPV and 169 
PPV for these modalities. Our study has addressed that knowledge gap by recruiting 205 170 
fetuses considered to be developing normally on USS; these were combined with the 171 
MERIDIAN results to estimate NPV and PPV. Predictive values indicate the precision of a 172 
diagnostic test, i.e. how likely the test is to find an abnormality when it actually exists (PPV) 173 
or how likely a test is to be negative if no abnormality exists (NPV) and are arguably more 174 
relevant to clinicians when making decisions on the basis of diagnostic tests.7,8 Traditionally, 175 
sensitivity and specificity have been the preferred measures of diagnostic performance, since 176 
the PPV and NPV depend on prevalence,9 indeed, the STARD checklist for diagnostic 177 
accuracy studies made only cursory mention of predictive values until the 2015 update.10,11 In 178 
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this study we have not attempted to estimate the sensitivity and specificity, since our two 179 
studies have (deliberately) not recruited random samples of pregnant women. The main 180 
MERIDIAN study evaluated iuMR in pregnancies where an abnormality was found on USS, 181 
with 570 fetuses included in the primary analysis. Since abnormal brain USS occurs in less 182 
than 1% of fetuses, a prospective study of all pregnancies would have needed more than 183 
57000 participants in order to recruit this number of brain abnormalities. By conducting two 184 
parallel studies we were able to study fetuses with normal and abnormal USS, but combining 185 
the two into one data set is inappropriate as doing so vastly over-represents by comparison to 186 
the general population, resulting in a biased estimate of both sensitivity and specificity. 187 
Although the sensitivity could - in theory - be derived by re-weighting the two studies to 188 
match population incidence, this would entail allocating a weight of less than 1% to the 189 
original MERIDIAN study with the remainder being allocated to the two cases identified in 190 
this study. A similar (though less extreme) situation applies to the specificity, and clearly this 191 
results in instable estimates which are best avoided. 192 
USS is offered to all women in the UK (and taken by >95%) so sensitivity and specificity of 193 
USS may be derived from routine patient notes.12 The diagnostic capability of USS has 194 
previously been quantified using sensitivity and specificity analysis by reviewing clinical 195 
cases that have been scanned as part of the routine screening process during pregnancy. A 196 
report by the National Institute for Health and Care Excellence (NICE)13 described the 197 
findings from those studies, showing that whilst the sensitivity of USS was variable (15% to 198 
85%) the specificity was consistently very high (99.4% to 100%). Rossi and Perfumo1 199 
attempted to define the diagnostic capability of iuMR using similar sensitivity and specificity 200 
measures but, as the vast majority of fetuses were initially suspected of being abnormal by 201 
USS, the truly normal pregnancies were again greatly under-represented and their findings do 202 
not adequately generalise to the wider population of pregnancies. Perhaps more importantly, 203 
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it is questionable whether the diagnostic ability of iuMR imaging needs to be evaluated 204 
among all pregnancies. Whilst neonatal screening relies heavily on USS, constraints on 205 
resource mean it is likely that iuMR will be used more selectively as a second-line screen for 206 
high risk pregnancies, most likely a suspected abnormality on USS± a position backed by the 207 
data from our study. There are more than 800,000 pregnancies in the UK each year,14 the 208 
majority of which undergo at least one USS, and the resource implications (trained expertise 209 
and financial) of providing iuMR routinely is prohibitive. It is interesting to note that the 210 
results of the adequately powered study reported by NICE13 were comparable to the NPV 211 
reported here.  212 
There are several possible limitations to our study, which primarily stem from recruiting 213 
µQRUPDO¶SDUWLFLSDQWV)LUVWO\WKHUHPD\EHDQHOHPHQWRIELDVZLWKLQWKHUHFUXLWPHQWSURFHVV214 
as it was reliant on volunteers. It is unclear if the women in our sample were fully 215 
representative of the obstetric population as, although recruited from a wide geographical 216 
area within the UK, we did not record demographics such as ethnicity. Secondly, it was not 217 
possible to restrict recruitment to women who could attend for iuMR shortly after USS as we 218 
were reliant on participants¶ availability. In theory the longer time period between USS and 219 
iuMR, the greater the possibility of abnormalities evolving and hence being visible on MR 220 
which would therefore biased the findings in favour of iuMR; in reality, the two modalities 221 
agreed in all bar two cases. The advantage to not restricting the time between USS and iuMR 222 
was that a wider age range of fetuses were scanned, and allowed a greater range of 223 
gestational age to be assessed since pregnant women are offered an anomaly screening USS 224 
EHWZHHQDQGZHHNV¶JHVWDWLRQ in the UK. Thirdly, the diagnostic accuracy of USS for 225 
this study was based on routine USS screening rather than USS by a fetal-maternal expert, 226 
which was a requirement of MERIDIAN. The availability of suitably qualified staff and the 227 
cost implications made this unattainable. It is impossible to ascertain whether the 2 cases with 228 
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abnormalities detected by iuMR were not present at USS or if they were missed. In the fetus 229 
with VM, there was 6 weeks between USS and iuMR, and in the second abnormal case there 230 
was 16 weeks. It was therefore possible that the abnormality was not present at the time of 231 
the USS and even if it was, it is impossible to say whether a fetal-maternal expert could have 232 
identified the abnormality.  233 
 234 
The consequences of abnormalities being missed on ante-natal USS are variable. Detecting 235 
abnormalities allows further investigations and additional monitoring of the pregnancy, or, if 236 
the abnormality is severe and detrimental to long term outcome allows the option of 237 
termination of pregnancy. Isolated mild VM is a common finding during pregnancy and a 238 
very high proportion have a favourable outcome, but iuMR is necessary to identify additional 239 
abnormalities.15-17 This finding therefore is perhaps less significant than the cortical 240 
abnormality diagnosed by iuMR in a fetus of 35 gw. Cortical dysplasia (or cortical tubers) is 241 
exceptionally difficult to identify by USS prenatally18 and can have a range of causes and 242 
outcomes. Earlier identification of this abnormality may not have changed the outcome in 243 
terms of health of the fetus, but would have provided vital information and allowed the 244 
parents to make an informed choice regarding its management. 245 
 246 
In conclusion, our results confirm the ability of both USS and iuMR to confirm when brain 247 
development of the fetus is normal. This highlights the validity of USS remaining as the 248 
primary screening imaging method for pregnancy, and further supports the need for 249 
additional iuMR imaging when abnormalities are detected on USS. However further research 250 
on fetuses at an increased risk of brain abnormality may be appropriate.19  251 
  252 
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TABLE LEGENDS 303 
Table 1. Data showing the agreement between ultrasonography (table 1a) and iuMR imaging 304 
(table 1b) when compared with outcome reference data. 305 
 306 
 307 
Table 1a:  308 
 Agreement with ORD  
Test finding 
USS 
correct 
USS 
incorrect 
 
    
USS abnormal*   388 182 PPV=68.1% (CI 64.1%-71.9%)  
USS normal 204 1 NPV=99.5% (CI 97.3%-100.0%)
 
 309 
 310 
 311 
Table 1b:  312 
 Agreement with ORD  
Test finding 
iuMR 
correct 
iuMR 
incorrect 
 
Following abnormal USS*    
iuMR abnormal 474 39 PPV=92.4% (CI 90.0%-94.5%)  
iuMR normal 56 1 NPV=98.2% (CI 90.6%-100.0%)
 
Following normal USS    
iuMR abnormal 2 0 PPV=100% (CI 15.9%-100%)  
iuMR normal 203 0 NPV=100% (CI 98.2%-100%)
 
 313 
* taken from original MERIDIAN cohort of fetuses with brain abnormality on USS 314 
 315 
 316 
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FIGURE LEGENDS 317 
Figure 1. Flow of participants through the study. 318 
 319 
Figure 2. Chart showing the number of fetuses scanned by gestational age. 320 
 321 
Figure 3. Single shot FSE image (3a), coronal (3b) and sagittal (3c) reconstruction from T2-322 
weighted 3D datasets show broadening of the right inferior frontal gyrus and abnormal white 323 
matter signal extending into the sub-central gyrus. These features were confirmed on post-324 
natal imaging (3d-3f). See text for details. 325 
 326 
Figure 4. Single shot FSE images (4a sagittal, 4b axial) show mild ventriculomegaly and 327 
macrocephaly (trigones of the lateral ventricles measured an axial reconstruction from a 3D 328 
dataset ± 4c). See text for details. 329 
 330 
